Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
- PMID: 34750053
- DOI: 10.1016/j.urolonc.2021.09.022
Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
Abstract
Intravesical Bacillus Calmette-Guérin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guérin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease.
Keywords: Bacillus Calmette-Guérin vaccine; Bladder cancer; Immunotherapy; Tuberculosis.
Copyright © 2021 Elsevier Inc. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
